Myriad, Gene and UnitedHealthcare

Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage
Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer cover the company's genetic test that helps to determine which mental health medications are likely to work with an individual patient.
Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight
Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests,
Myriad Genetics comments on UnitedHealthcare’s updated policy
Myriad Genetics (MYGN) was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to
Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes
Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said.
Myriad weakness due to UnitedHealth coverage update, says Stephens
Stephens analyst Mason Carrico notes that Myriad Genetics (MYGN) shares are down about 20% this morning, which the firm blames on an announcement from UnitedHealth (UNH) stating that starting Jan. 1,
bovnews1d
The Myriad Genetics, Inc. Rollercoaster: What’s Behind the Latest MYGN Stock Fluctuation?
On Friday, Myriad Genetics, Inc. (MYGN) stock saw a decline, ending the day at $17.99 which represents a decrease of $-3.97 or -18.08% from the prior close of $21.96. The stock opened at $20.04 and ...
TD Cowen Reaffirms Their Hold Rating on Myriad Genetics (MYGN)
TD Cowen analyst Daniel Brennan maintained a Hold rating on Myriad Genetics (MYGN – Research Report) today and set a price target of ...
Zacks.com on MSN9d
Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?
Myriad Genetics (MYGN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook ...
Nasdaq4d
Myriad Genetics Enters Oversold Territory (MYGN)
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Myriad Genetics, Inc. (Symbol: MYGN) entered into oversold territory, hitting an RSI reading ...
360dx4d
360Dx Top 30 Falls 3 Percent in October
Out of the 30 companies tracked by 360Dx, 22 saw their share prices decline, seven saw their stock prices increase, and one company’s shares remained essentially flat.